Regeneron
OrganizationRelationship Network
Event Timeline
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
organization
Sanofi
|
Business associate |
11
Very Strong
|
4 | |
|
organization
AMG
|
Competitors |
7
|
1 | |
|
person
Leonard Schleifer
|
Founder and ceo |
5
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| N/A | N/A | The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia a... | N/A | View |
| N/A | N/A | Trading of Regeneron shares was halted pending news. | N/A | View |
| 2025-12-01 | N/A | ODYSSEY clinical trial program. | N/A | View |
| 2015-09-01 | N/A | Expected final decision by European Commission on Marketing Authorization Application | European Union | View |
| 2015-07-24 | N/A | Investor Relations Conference Call hosted by Sanofi and Regeneron to discuss Praluent. | Teleconference / Webcast | View |
| 2015-07-24 | N/A | Investor Relations Conference Call on Praluent hosted by Sanofi and Regeneron | Conference Call / Webcast | View |
| 2015-07-24 | N/A | Investor Relations Conference Call on Praluent for the financial community. | Teleconference / Webcast | View |
HOUSE_OVERSIGHT_023087.jpg
This document is page 19 of a 'Equity Strategy Focus Point' report produced by Bank of America Merrill Lynch on January 29, 2017. It presents a table of S&P 500 companies identified as potential beneficiaries of a lower US corporate tax rate due to their high effective tax rates and low foreign sales exposure. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production to the House Oversight Committee.
HOUSE_OVERSIGHT_025891.jpg
This document is a press release or investor relations update from Sanofi and Regeneron dated around July 2015, detailing clinical trial results, pricing, and regulatory milestones for the cholesterol drug Praluent. It announces a positive opinion from the European Medicine Agency and schedules an investor conference call for July 24, 2015. The document bears a 'HOUSE_OVERSIGHT' footer, suggesting it was part of a document production to Congress, likely related to pharmaceutical pricing or regulatory investigations, though it contains no direct mentions of Jeffrey Epstein or his associates in this specific page.
HOUSE_OVERSIGHT_025890.jpg
This document appears to be a printout of a news article or press release compilation regarding the FDA approval and market analysis of the Regeneron/Sanofi cholesterol drug, Praluent. It details financial projections, physician surveys, and quotes from executives at Regeneron, Sanofi, and CVS Caremark regarding pricing and accessibility. While the document bears a House Oversight stamp and mentions Donald Trump in a disconnected headline, the content focuses entirely on the pharmaceutical industry.
HOUSE_OVERSIGHT_025889.jpg
This document discusses the approval, benefits, and high cost of a new cholesterol-lowering drug called Praluent, noting its potential expense concerns raised by CVS Caremark executive Troy Brennan. It details the FDA's approval criteria, focusing on patients with genetic conditions or previous heart disease, and mentions the pricing strategy by Regeneron and Sanofi amidst competition from Amgen. The bottom half of the page lists "Recommended by Forbes" article links.
HOUSE_OVERSIGHT_025888.jpg
This document is an email from Sultan Bin Sulayem to Jeffrey Epstein dated July 24, 2015. Sulayem forwards a Forbes article regarding the FDA approval of a new cholesterol-lowering drug called Praluent (by Regeneron Pharmaceuticals) and asks Epstein if he has heard of it. The document bears a House Oversight Bates stamp.
HOUSE_OVERSIGHT_026365.jpg
This document is a press release from pharmaceutical companies Sanofi and Regeneron regarding their cholesterol drug, Praluent (alirocumab). It announces the drug's approval based on clinical trial data, its U.S. price of $40 per day, and the launch of patient support programs. The release also advertises an investor relations conference call scheduled for July 24, 2015, and notes a pending marketing authorization decision in the European Union.
HOUSE_OVERSIGHT_026364.jpg
This article discusses the new cholesterol drug, Praluent, from Regeneron and Sanofi, focusing on its high price, which is 46% higher than analyst forecasts. It details the FDA's approval for a broader patient group than expected, the potential for wide prescription by doctors despite the label, and the expected resistance from insurance companies who will likely restrict its use. The article also includes commentary from executives at Regeneron and Sanofi, as well as analysts and cardiologists, on the drug's market potential and place alongside existing treatments like statins.
HOUSE_OVERSIGHT_026363.jpg
This document is a printout of an article, likely from Forbes circa 2015, discussing a new cholesterol drug, Praluent. The article details the drug's effectiveness, its high cost ($14,600/year), and the companies involved, such as Regeneron, Sanofi, and Amgen. Although the document has a 'HOUSE_OVERSIGHT' Bates number, its content does not contain any explicit mention of Jeffrey Epstein or related individuals, and its relevance to that case is not apparent from the text itself.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity